The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Lipoprotein(a): resurrected by genetics
Open accessAbstract
Plasma lipoprotein(a) [L p(a)] is a quantitative genetic trait with a very broad and skewed distribution, which is largely controlled by genetic variants at the LPA locus on chromosome 6q27. Based on genetic evidence provided by studies conducted over the last two decades, L p(a) is currently considered to be the strongest genetic risk factor for coronary heart disease (CHD). The copy number variation of kringle IV in the LPA gene has been strongly associated with both L p(a) levels in plasma and risk of CHD, thereby fulfilling the main criterion for causality in a M endelian randomization approach. Alleles with a low kringle IV copy number that together have a population frequency of 25–35% are associated with a doubling of the relative risk for outcomes, which is exceptional in the field of complex genetic phenotypes. The recently identified binding of oxidized phospholipids to L p(a) is considered as one of the possible mechanisms that may explain the pathogenicity of L p(a). Drugs that have been shown to lower L p(a) have pleiotropic effects on other CHD risk factors, and an improvement of cardiovascular endpoints is up to now lacking. However, it has been established in a proof of principle study that lowering of very high L p(a) by apheresis in high‐risk patients with already maximally reduced low‐density lipoprotein cholesterol levels can dramatically reduce major coronary events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [221]
In the citing paper
“When the size of apolipoprotein (a) [apo(a)] is small, the concentration of Lp(a) is high, and there is a high risk of CVD.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [221]
In the citing paper
“Lp(a) is an independent risk factor for CAD and stroke.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Research works printed but not linked: 2
- Utermann G, 2000, The Metabolic & Molecular Bases of Inherited Disease, 2753
- 10.1210/jc.81.7.2633 · DOI
Cited by
Sorted by citations
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Padmanabhan, A., Connelly‐Smith, L. S., Aqui, N. A., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,260
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationA Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“Apo(a) is synthesized almost exclusively in the liver, but the site of assembly of Lp(a) has not been confirmed, and may be within the hepatocyte, the space of Disse, or the plasma compartment (7).”
BackgroundKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K. B., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 843
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Structure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Self-citationNordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 522
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
de Ferranti, S. D., Steinberger, J., Ameduri, R. K., Baker, A., Gooding, H. C., Kelly, A. S., Mietus‐Snyder, M., Mitsnefes, M. M., Peterson, A. L. H., St‐Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 464
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups
Paré, G., Çaku, A., McQueen, M., Anand, S. S., Enas, E. A., Clarke, R., Boffa, M. B., Koschinsky, M. L., Wang, X., Yusuf, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034311 · Cited by 385
Segmental duplications and their variation in a complete human genome
Vollger, M. R., Guitart, X., Dishuck, P. C., Mercuri, L., Harvey, W. T., Gershman, A., Diekhans, M., Sulovari, A., Munson, K. M., Lewis, A. P., et al. (2022) · Science · doi:10.1126/science.abj6965 · Cited by 350
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Boffa, M. B., & Koschinsky, M. L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r060582 · Cited by 309
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 315
High lipoprotein(a) and high risk of mortality
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy902 · Cited by 288
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
Willeit, P., Kiechl, S., Kronenberg, F., Witztum, J. L., Santer, P., Mayr, M., Xu, Q., Mayr, A., Willeit, J., & Tsimikas, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.061 · Cited by 286
Self-citationPathophysiology and treatment of atherosclerosis
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 299
Langsted, A., Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30042-0 · Cited by 270
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Elevated Lipoprotein(a) and Risk of Ischemic Stroke
Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.524 · Cited by 272
Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260
Self-citationVarbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)
Leibundgut, G., Scipione, C. A., Yin, H., Schneider, M., Boffa, M. B., Green, S., Yang, X., Dennis, E. A., Witztum, J. L., Koschinsky, M. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m040733 · Cited by 246
Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 246
Self-citationPreclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239
Saleheen, D., Haycock, P., Zhao, W., Rasheed, A., Taleb, A., Imran, A., Abbas, S., Majeed, F., Akhtar, S., Qamar, N., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30088-8 · Cited by 238
Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307983 · Cited by 227
Self-citationHuman Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 233
Self-citationLipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Gudbjartsson, D. F., Þorgeirsson, G., Sulem, P., Helgadóttir, A., Gylfason, A., Saemundsdottir, J., Björnsson, E., Norddahl, G. L., Jónasdóttir, Á., Jónasdóttir, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.019 · Cited by 227
Coassin, S., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.003 · Cited by 231
Self-citationLamina, C., & Kronenberg, F. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1041 · Cited by 225
Self-citationEffect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Yeang, C., Karwatowska‐Prokopczuk, E., Su, F., Dinh, B., Xia, S., Witztum, J. L., & Tsimikas, S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.032 · Cited by 222
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211
Self-citationSantos, R. D., Raal, F. J., Catapano, A. L., Witztum, J. L., Steinhagen‐Thiessen, E., & Tsimikas, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304549 · Cited by 197
Gencer, B., Kronenberg, F., Stroes, E. S. G., & Mach, F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx033 · Cited by 189
Self-citationMack, S., Coassin, S., Rueedi, R., Yousri, N. A., Seppälä, I., Gieger, C., Schönherr, S., Forer, L., Erhart, G., Marques-Vidal, P., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076232 · Cited by 186
Self-citationHigh-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)
Zhang, W., Speiser, J. L., Ye, F., Tsai, M. Y., Cainzos‐Achirica, M., Nasir, K., Herrington, D. M., & Shapiro, M. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.016 · Cited by 169
The role of lipoprotein (a) in chronic kidney disease
Hopewell, J. C., Haynes, R., & Baigent, C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083626 · Cited by 164
Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?
Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.008 · Cited by 156
Self-citationPoly-ADP-ribosylation in health and disease
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 157
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 148
Laschkolnig, A., Kollerits, B., Lamina, C., Meisinger, C., Rantner, B., Stadler, M., Peters, A., Köenig, W., Stockl, A., Dahnhardt, D., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu107 · Cited by 146
Self-citationKamstrup, P. R., & Nordestgaard, B. G. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70064-0 · Cited by 147
LPA Gene, Ethnicity, and Cardiovascular Events
Lee, S. R., Prasad, A., Choi, Y. S., Xing, C., Clopton, P., Witztum, J. L., & Tsimikas, S. (2016) · Circulation · doi:10.1161/circulationaha.116.024611 · Cited by 141
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G. C., Mach, F., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.04.012 · Cited by 146
Self-citationLangsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
Simony, S. B., Mortensen, M. B., Langsted, A., Afzal, S., Kamstrup, P. R., & Nordestgaard, B. G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1023 · Cited by 134
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133
Causes and consequences of lipoprotein(a) abnormalities in kidney disease
Kronenberg, F. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0875-8 · Cited by 128
Self-citationPCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
Villard, E. F., Thedrez, A., Blankenstein, J., Croyal, M., Tran, T.-T.-T., Poirier, B., Le Bail, J.-C., Illiano, S., Nobécourt, E., Krempf, M., et al. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.006 · Cited by 113
Enas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.03.004 · Cited by 128
Perrot, N., Verbeek, R., Sandhu, M. S., Boekholdt, S. M., Hovingh, G. K., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.010 · Cited by 120
Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs
Stefanutti, C., Julius, U., Watts, G. F., Harada‐Shiba, M., Cossu, M., Schettler, V. J. J., Silvestro, G. D., Soran, H., van Lennep, J. E. R., Pisciotta, L., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.114 · Cited by 119
Lp(a): When and how to measure it
Cegla, J., France, M. W., Marcovina, S. M., & Neely, R. D. G. (2020) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563220968473 · Cited by 123
Scharnagl, H., Stojaković, T., Dieplinger, B., Dieplinger, H., Erhart, G., Kostner, G. M., Herrmann, M., März, W., & Grammer, T. B. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.015 · Cited by 115
Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related macular degeneration.
Handa, J. T., Cano, M., Wang, L., Datta, S., & Liu, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.013 · Cited by 112
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 119
Vongpromek, R., Bos, S., ten Kate, G. R., Yahya, R., Verhoeven, A. J. M., de Feyter, P. J., Kronenberg, F., van Lennep, J. E. R., Sijbrands, E. J. G., & Mulder, M. T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12335 · Cited by 110
Self-citationClinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 112
Sahebkar, A., Simental‐Mendía, L. E., Pirro, M., Banach, M., Watts, G. F., Sirtori, C. R., Al‐Rasadi, K., & Atkin, S. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-36204-7 · Cited by 105
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 109
Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes
Jakubiak, G. K., Pawlas, N., Cieślar, G., & Stanek, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182211970 · Cited by 107
Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.049 · Cited by 103
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103
Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
Bonde, Y., Breuer, O., Lütjohann, D., Sjöberg, S., Angelin, B., & Rudling, M. J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051664 · Cited by 110
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
Ding, L., Song, A., Dai, M., Xu, M., Sun, W., Xu, B., Sun, J., Wang, T., Xu, Y., Lu, J., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p049015 · Cited by 96
Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood
Raitakari, O. T., Kartiosuo, N., Pahkala, K., Hutri‐Kähönen, N., Bazzano, L., Chen, W., Urbina, E. M., Jacobs, D. R., Sinaiko, A. R., Steinberger, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060667 · Cited by 96
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93
Coassin, S., Erhart, G., Weissensteiner, H., Eca Guimarães de Araújo, M., Lamina, C., Schönherr, S., Forer, L., Haun, M., Losso, J. L., Köttgen, A., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx174 · Cited by 93
Self-citationLipoprotein apheresis for lipoprotein(a) and cardiovascular disease
Moriarty, P. M., Gray, J. V., & Gorby, L. K. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.09.010 · Cited by 89
Chan, D. C., Pang, J., Hooper, A. J., Burnett, J. R., Bell, D. A., Bates, T. R., BOCKXMEER, F. M. V., & Watts, G. F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.146 · Cited by 89
Cobbaert, C. M., Althaus, H., Brkovic, I. B., Ceglarek, U., Coassin, S., Delatour, V., Deprez, L., Dikaios, I., Dittrich, J., Hoofnagle, A. N., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa239 · Cited by 88
Self-citationThe Brussels International Declaration on Lipoprotein(a) Testing and Management
Kronenberg, F., Bedlington, N., Ademi, Z., Geantă, M., Silberzahn, T., Rijken, M., Kaal, A., Harada‐Shiba, M., Chen, Z., Thanassoulis, G., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119218 · Cited by 88
Self-citationLipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
Cesaro, A., Schiavo, A., Moscarella, E., Coletta, S., Conte, M., Gragnano, F., Fimiani, F., Monda, E., Caiazza, M., Limongelli, G., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001077 · Cited by 84
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 89
Porcine models for studying complications and organ crosstalk in diabetes mellitus
Renner, S., Blutke, A., Clauß, S., Deeg, C. A., Kemter, E., Merkus, D., Wanke, R., & Wolf, E. (2020) · Cell and Tissue Research · doi:10.1007/s00441-019-03158-9 · Cited by 94
Schachtl‐Riess, J. F., Kheirkhah, A., Grüneis, R., Maio, S. D., Schoenherr, S., Streiter, G., Losso, J. L., Paulweber, B., Eckardt, K., Köttgen, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.037 · Cited by 82
Self-citationResidual cardiovascular risk: When should we treat it?
Gómez-Delgado, F., Raya‐Cruz, M., Katsiki, N., Delgado‐Lista, J., & Pérez‐Martínez, P. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.013 · Cited by 82
Hoekstra, M., Chen, H. Y., Rong, J., Dufresne, L., Yao, J., Guo, X., Tsai, M. Y., Tsimikas, S., Post, W. S., Vasan, R. S., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314965 · Cited by 80
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 84
Trinder, M., DeCastro, M. L., Azizi, H., Cermakova, L., Jackson, L. M., Frohlich, J., Mancini, G. B. J., Francis, G. A., & Brunham, L. R. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.065 · Cited by 76
Enas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.04.007 · Cited by 76
Rodrigo Alonso, K., Mata, P., Muñiz-Grijalvo, O., Fuentes, F. J., Díaz, J. L., Zambón, D., Tomás, M., Martı́n, C., Moyon, T., Croyal, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.038 · Cited by 74
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease
Bajaj, A., Damrauer, S. M., Anderson, A. H., Xie, D., Budoff, M. J., Go, A. S., He, J., Lash, J. P., OJO, A. O., Post, W. S., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309920 · Cited by 69
Markers of Atherosclerosis: Part 1 – Serological Markers
Tibaut, M., Čaprnda, M., Kubatka, P., Sinkovič, A., Valentová, V., Filipová, S., Gazdíková, K., Gašpar, Ľ., Mozos, I. M., Egom, E. E. A., et al. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.06.1057 · Cited by 74
PCSK9 in chronic kidney disease
Pavlakou, P., Liberopoulos, E. N., Dounousi, E. C., & Elisaf, M. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1505-2 · Cited by 68
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 65
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Kronenberg, F., Mora, S., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000855 · Cited by 68
Self-citationHedegaard, B. S., Bork, C. S., Kaltoft, M., Klausen, I. C., Schmidt, E. B., Kamstrup, P. R., Langsted, A., & Nordestgaard, B. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.021 · Cited by 69
Laskar, M. G., Eriksson, M., Rudling, M. J., & Angelin, B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12594 · Cited by 67
Metadata
- Authors
- Kronenberg, F., & Utermann, G.
- Affiliations
- Innsbruck Medical University (AT)
- Corresponding author
- Utermann, G.
- ORCID
- Kronenberg, F.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2012-11-12
- Volume
- 273
- Issue
- 1
- Pages
- 6-30
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1988877980
- Cited by
- 521
- References
- 203
- Citations by year
- 2026: 40 · 2025: 38 · 2024: 39 · 2023: 41 · 2022: 45 · 2021: 42 · 2020: 36 · 2019: 48 · 2018: 35 · 2017: 36 · 2016: 42 · 2015: 38 · 2014: 20 · 2013: 17 · 2012: 2
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund
- Oesterreichische Nationalbank
- Standortagentur Tirol
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- lipoprotein(a), LPA gene, coronary heart disease risk, genetic risk factors, Mendelian randomization, apheresis, cardiovascular risk reduction
- MeSH terms
- Alleles, Coronary Artery Disease, DNA, Gene Frequency, Humans, Polymorphism, Genetic, Lipoprotein(a), Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
